The word “compounded” shows up all over GLP-1 marketing, and it rarely gets explained. Here is the plain version: a compounded drug is one that a state-licensed or outsourcing pharmacy prepares itself, for a specific patient, instead of the finished, FDA-approved product that a manufacturer makes at scale. The active ingredient may be the same molecule, but the finished compounded preparation has not been through FDA approval, and that difference matters.
Compounded is not the same as the brand-name drug
A brand-name GLP-1 is a specific, FDA-approved product: a defined formulation, dose, and manufacturing standard reviewed by the agency. A compounded version is prepared by a pharmacy and is not FDA-approved, even when it uses the same underlying molecule. It is accurate to say a compounded preparation contains semaglutide or tirzepatide. It is not accurate, and we will not say, that it is “the same as” any branded product. The formulation, testing, and regulatory status are different, and honest language here is the whole point.
Why compounded GLP-1 existed, and what changed
For a stretch, semaglutide and tirzepatide sat on the FDA drug-shortage list, and federal rules allow compounding pharmacies to prepare a drug that is in shortage so patients keep access. Those injection shortages were later declared resolved. In 2026 the FDA moved further, proposing to exclude semaglutide, tirzepatide, and liraglutide from the list that lets outsourcing facilities compound them from bulk ingredient, on the view that there is no longer a clinical need to. The regulatory ground under compounded GLP-1 is genuinely shifting, which is exactly why understanding the category matters before you buy into it.
you are
Add what fits. Consent happens at checkout, prescriptions come from independent licensed providers, and weight and hormone paths include a consult. Browse the shop →
503A and 503B: two kinds of pharmacy
Compounding happens in two settings. A 503A pharmacy compounds for an individual patient against a specific prescription. A 503B outsourcing facility compounds larger batches under tighter federal oversight. Both are legitimate parts of the system when used correctly, and both are distinct from a brand manufacturer. The affiliated medical group and its pharmacy partners work within these rules; the category is defined by them, not around them.
What safety monitoring looks like
Compounded products carry the same active-drug considerations as any GLP-1, plus the added reality that the finished preparation has not been FDA-reviewed. Regulators have logged adverse-event reports tied to compounded semaglutide and tirzepatide, which is one more reason a compounded option belongs inside a monitored clinical relationship rather than a one-click cart. That means a baseline metabolic panel, a real prescriber, and follow-up. (See the GLP-1 metabolic panel and tirzepatide vs semaglutide.)
What your physician does with this (labs before molecules)
At Telos the model is measure first. The information you share and the panel you complete are reviewed by a licensed physician through the affiliated medical group, who reads your metabolic markers and history and decides whether any GLP-1 option, compounded or otherwise, fits. Telos markets and refers; it does not prescribe, dispense, or take payment for care. Nothing here is medical advice, and a compounded preparation is never presented as equivalent to an approved brand-name drug.
